PE20060358A1 - Cristal estable del compuesto 4-oxoquinolina - Google Patents

Cristal estable del compuesto 4-oxoquinolina

Info

Publication number
PE20060358A1
PE20060358A1 PE2005000561A PE2005000561A PE20060358A1 PE 20060358 A1 PE20060358 A1 PE 20060358A1 PE 2005000561 A PE2005000561 A PE 2005000561A PE 2005000561 A PE2005000561 A PE 2005000561A PE 20060358 A1 PE20060358 A1 PE 20060358A1
Authority
PE
Peru
Prior art keywords
crystal
stable crystal
oxoquinoline compound
diffration
forms
Prior art date
Application number
PE2005000561A
Other languages
English (en)
Inventor
Motohide Satoh
Takahisa Motomura
Kentaro Kondo
Koji Matsuda
Hideto Uehara
Shuji Miyake
Koji Ando
Takashi Matsuda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20060358A1 publication Critical patent/PE20060358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

REFERIDA A UN CRISTAL DEL ACIDO 6-(3-CLORO-2-FLUOROBENCIL)-1-[(S)-1-HIDROXIMETIL-2-METILPROPIL]-7-METOXI-4-OXO-1,4-DIHIDROQUINOLINA-3-CARBOXILICO, QUE MUESTRA PICOS MAXIMOS DE DIFRACCION CARACTERISTICOS A ANGULOS DE DIFRACCION 2q(°) MEDIDO MEDIANTE DIFRACTOMETRIA DE POLVO POR RAYOS-X, TALES COMO 6,56, 13,20, 19,86, 20,84, 21,22, 24,22. SON FORMAS CARACTERISTICAS DE ESTE CRISTAL, LAS FORMAS II Y III. DICHO CRISTAL PRESENTA UNA ESTABILIDAD FISICA Y QUIMICA MEJORADA
PE2005000561A 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina PE20060358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
PE20060358A1 true PE20060358A1 (es) 2006-05-12

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011002129A PE20120361A1 (es) 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico
PE2005000561A PE20060358A1 (es) 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011002129A PE20120361A1 (es) 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico

Country Status (30)

Country Link
US (6) US7635704B2 (es)
EP (4) EP2514746A1 (es)
JP (1) JP3754064B2 (es)
KR (1) KR20080064909A (es)
CN (1) CN1956961B (es)
AR (2) AR049280A1 (es)
AU (1) AU2005245296B2 (es)
BR (1) BRPI0510114B8 (es)
CA (1) CA2566922C (es)
CY (1) CY1113010T1 (es)
DK (2) DK1636190T3 (es)
ES (2) ES2388441T3 (es)
FI (2) FI3281939T3 (es)
HK (1) HK1083341A1 (es)
HR (2) HRP20231588T3 (es)
IL (1) IL179250A0 (es)
LT (1) LT3281939T (es)
MX (1) MXPA06013405A (es)
MY (1) MY134672A (es)
NO (6) NO20230913A1 (es)
NZ (1) NZ551839A (es)
PE (2) PE20120361A1 (es)
PL (2) PL3281939T3 (es)
PT (2) PT3281939T (es)
RS (2) RS52375B (es)
RU (1) RU2330845C1 (es)
SI (2) SI3281939T1 (es)
TW (1) TWI329015B (es)
WO (1) WO2005113508A1 (es)
ZA (1) ZA200610647B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
EP3406596A1 (en) * 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2006332664B2 (en) * 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
EP1978960A4 (en) * 2006-02-01 2009-12-02 Japan Tobacco Inc USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
US8383819B2 (en) 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
AP2985A (en) 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
NZ579802A (en) * 2007-02-23 2012-04-27 Gilead Sciences Inc Compounds for improving the efficacy of other drugs
US20110009411A1 (en) * 2007-06-29 2011-01-13 Gilead Sciences ,Inc. Therapeutic compositions and the use thereof
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
SI2393485T1 (sl) 2009-02-06 2015-10-30 Gilead Sciences, Inc. Dvoslojne tablete, ki vsebujejo elvitegravir, cobicistat, emtricitabin in tenofovir
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
MX2015000164A (es) 2012-07-06 2015-08-12 Genentech Inc Benzamidas n-sustituidas y metodos para usarlas.
ES2608860T3 (es) 2012-08-03 2017-04-17 Gilead Sciences, Inc. Proceso e intermedios para preparar inhibidores de la integrasa
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
KR102040007B1 (ko) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
ES2645192T3 (es) 2013-07-12 2017-12-04 Gilead Sciences, Inc. Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (es) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (es) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3736274A1 (en) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (es) 1970-09-14 1981-02-16
JPS4826772A (es) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
AU683569B2 (en) 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ES2171260T3 (es) 1996-04-12 2002-09-01 Us Gov Health & Human Serv Compuestos derivados de acridona utiles como agentes antineoplasicos y antirretroviricos.
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
ATE411292T1 (de) 2001-03-01 2008-10-15 Shionogi & Co Stickstoffhaltige heteroarylverbindungen mit hiv- integrase inhibierender wirkung
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EP3406596A1 (en) * 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors

Also Published As

Publication number Publication date
ES2960824T3 (es) 2024-03-06
PL3281939T3 (pl) 2024-03-18
CA2566922C (en) 2011-01-11
AU2005245296B2 (en) 2010-08-12
US20180029989A1 (en) 2018-02-01
HRP20120681T1 (hr) 2012-09-30
TW200600097A (en) 2006-01-01
US8981103B2 (en) 2015-03-17
HRP20231588T3 (hr) 2024-03-15
LT3281939T (lt) 2023-11-27
PT3281939T (pt) 2023-11-22
JP3754064B2 (ja) 2006-03-08
DK1636190T3 (da) 2012-09-24
NO20220690A1 (no) 2007-02-07
NO20230913A1 (no) 2007-02-07
IL179250A0 (en) 2007-03-08
CY1113010T1 (el) 2016-04-13
ZA200610647B (en) 2008-06-25
EP4299563A3 (en) 2024-02-28
TWI329015B (en) 2010-08-21
EP1636190A1 (en) 2006-03-22
BRPI0510114A (pt) 2007-09-25
RS64845B1 (sr) 2023-12-29
EP3281939A1 (en) 2018-02-14
CN1956961B (zh) 2010-05-26
NO20190051A1 (no) 2007-02-07
SI1636190T1 (sl) 2012-09-28
AR049280A1 (es) 2006-07-12
NZ551839A (en) 2009-11-27
WO2005113508A1 (en) 2005-12-01
EP3281939B1 (en) 2023-10-18
MXPA06013405A (es) 2007-03-01
NO339223B1 (no) 2016-11-21
KR20080064909A (ko) 2008-07-09
NO20200873A1 (no) 2007-02-07
CN1956961A (zh) 2007-05-02
JP2006001927A (ja) 2006-01-05
US20060030710A1 (en) 2006-02-09
CA2566922A1 (en) 2005-12-01
BRPI0510114B1 (pt) 2020-09-15
US20220235009A1 (en) 2022-07-28
FI3281939T3 (fi) 2023-10-23
FIC20240008I1 (fi) 2024-03-20
BRPI0510114B8 (pt) 2021-05-25
DK3281939T3 (da) 2024-01-22
AR096100A2 (es) 2015-12-09
ES2388441T3 (es) 2012-10-15
SI3281939T1 (sl) 2024-02-29
HK1083341A1 (en) 2006-06-30
US20190185433A1 (en) 2019-06-20
PT1636190E (pt) 2012-08-20
US7635704B2 (en) 2009-12-22
EP1636190B1 (en) 2012-06-27
NO20065790L (no) 2007-02-07
US20100204271A1 (en) 2010-08-12
EP4299563A2 (en) 2024-01-03
AU2005245296A1 (en) 2005-12-01
US20150361044A1 (en) 2015-12-17
MY134672A (en) 2007-12-31
NO20161297A1 (no) 2007-02-07
PL1636190T3 (pl) 2012-10-31
EP2514746A1 (en) 2012-10-24
RU2330845C1 (ru) 2008-08-10
PE20120361A1 (es) 2012-05-03
RS52375B (en) 2012-12-31

Similar Documents

Publication Publication Date Title
PE20060358A1 (es) Cristal estable del compuesto 4-oxoquinolina
UY38793A (es) Compuestos químicos
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
MX2015016303A (es) Uso de derivados del acido tetramico como nematicidas.
BR112013004220A2 (pt) fenilamidinas tendo uma atividade fungicida alta e seu uso.
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
CO6541658A2 (es) Derivados de pirazol como inhibidores de jak
CL2013001295A1 (es) Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
UY30663A1 (es) Dihidropirazolonas sustituidas y su uso
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UA116809C2 (uk) Застосування агрохімічних сумішей для збільшення життєздатності рослини
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
UY34737A (es) ?compuestos herbicidas, composiciones, metodos de control de malezas y uso de dichos compuestos?.
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CU23944B1 (es) Amidas del ácido pirrolidin-1,2-dicarboxílico sustituidas como moduladores de calicreína 7
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
SE0800742L (sv) Vikttäcke
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
MX2011012533A (es) Espiro-epoxidos como productos intermedios.
BR112015028876A2 (pt) derivados de perhidroquinoxalina
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.

Legal Events

Date Code Title Description
FG Grant, registration